Sharp Neurocognitive Research Center

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease5 trials
• Mild cognitive impairment2 trials

Phase

• Phase 33 trials
• Phase 21 trial

Status

• Active, not recruiting3 trials
• Completed1 trial
• Enrolling by invitation1 trial

Lead sponsor

• Eli Lilly and Company2 trials
• University of Southern California2 trials
• Eisai Inc.1 trial

Running trials

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Eli Lilly and Company· Source

• Enrolling by invitation

  Alzheimer's Plasma Extension

  NCT06416072· University of Southern California· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

  NCT03887455· Phase 3· Eisai Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease1 recruiting

Closed trials

• Completed

  Memory Improvement Through Nicotine Dosing (MIND) Study

  NCT02720445· Phase 2· University of Southern California· Source